Wei Cai

Wei Cai

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
WCWei Cai
Wei Cai
KTKristin Tolksdorf
Kristin Tolksdorf
SHSiddhivinayak Hirve
Siddhivinayak Hirve
ESEkkehard Schuler
Ekkehard Schuler
WZWenqing Zhang
Wenqing Zhang
SBSilke Buda
Silke Buda
Background: Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection (ALRI) in young children. ICD‐10‐based syndromic surveillance can transmit data rapidly in a standardized way.Objectives: We investigated the use of RSV‐specific ICD‐10 codes for RSV surveillance.Methods: We performed a retrospective descriptive data analysis based on existing ICD‐10‐based surveillance systems for ALRI in primary and secondary care and a linked virological surveillance in Germany. We described RSV epidemiology and compared the epidemiological findings based on ICD‐10 and virological data. We calculated sensitivity and specificity of RSV‐specific ICD‐10 codes and in combination with ICD‐10 codes for acute respiratory infections (ARI) for the identification of laboratory‐confirmed RSV infections.Results: Based on the ICD‐10 and virological data, epidemiology of RSV was described, and common findings were found. The RSV‐specific ICD‐10 codes had poor sensitivity 6% (95%‐CI: 3%‐12%) and high specificity 99.8% (95%‐CI: 99.6%‐99.9%). In children <5 years and in RSV seasons, the sensitivities of RSV‐specific ICD‐10 codes combined with general ALRI ICD‐10 codes J18.‐, J20.‐ and with J12.‐, J18.‐, J20.‐, J21.‐, J22 were moderate (44%, 95%‐CI: 30%‐59%). The specificities of both combinations remained high (91%, 95%‐CI: 86%‐94%; 90%, 95%‐CI: 85%‐94%).Conclusions: The use of RSV‐specific ICD‐10 codes may be a useful indicator to describe RSV epidemiology. However, RSV‐specific ICD‐10 codes underestimate the number of actual RSV infections. This can be overcome by combining RSV‐specific and general ALRI ICD‐10 codes. Further investigations are required to validate this approach in other settings.

16 February 2020 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
WCWei Cai
Wei Cai
SBSilke Buda
Silke Buda
ESEkkehard Schuler
Ekkehard Schuler
SHSiddhivinayak Hirve
Siddhivinayak Hirve
WZWenqing Zhang
Wenqing Zhang
WHWalter Haas
Walter Haas
Introduction: Respiratory syncytial virus (RSV) is a major cause of hospital admission for acute lower respiratory tract infection in young children.Objectives: We aimed to identify risk factors for hospitalized RSV disease and its severe outcomes.Methods: We conducted a retrospective cohort study analyzing data of a ICD‐10‐code‐based hospital surveillance for severe acute respiratory infections (SARI). Using univariable and multivariable logistic regression analysis, we assessed age‐group, gender, season, and underlying medical conditions as possible risk factors for RSV and its severe outcomes including ICU admission, application of ventilator support, and death, respectively.Results: Of the 413 552 patients hospitalized with SARI in the database, 8761 were diagnosed with RSV from week 01/2009 to 20/2018 with 97% (8521) aged <5 years. Among children aged <5 years, age‐groups 0‐5 months (OR: 20.29, 95% CI: 18.37‐22.41) and 6 months‐1 year (OR: 4.59, 95% CI: 4.16‐5.06), and underlying respiratory and cardiovascular disorders specific to the perinatal period (OR: 1.32, 95% CI: 1.11‐1.57) were risk factors for being diagnosed with RSV. Age‐group 0‐5 months (OR: 2.39, 95% CI: 1.45‐3.94), low birth weight (OR: 6.77, 95% CI: 1.28‐35.71), preterm newborn (OR: 6.71, 95% CI: 2.19‐20.61), underlying respiratory and cardiovascular disorders specific to the perinatal period (OR: 4.97, 95% CI: 3.36‐7.34), congenital malformation of the heart (OR: 3.65, 95% CI: 1.90‐7.02), congenital malformation of the great vessels (OR: 3.50, 95% CI: 1.10‐11.18), congenital defect originating in perinatal period (OR: 4.07, 95% CI: 1.71‐9.70), cardiovascular disease (OR: 5.19, 95% CI: 2.77‐9.72), neurological disorders (OR: 6.48, 95% CI: 3.76‐11.18), blood disease (OR: 3.67, 95% CI: 1.98‐6.79), and liver disease (OR: 14.99, 95% CI: 1.49‐150.82) contributed to ICU admission in RSV cases.Conclusions: Using ICD‐10‐based surveillance data allows to identify risk factors for hospitalized RSV disease and its severe outcomes, and quantify the risk in different age‐groups.

5 September 2016 in BMC Public Health
Verified
Journal Article
Open access
PDF file
TGthe DRUCK Study group
the DRUCK Study group
BWBenjamin Wenz
Benjamin Wenz
SNStine Nielsen
Stine Nielsen
MGMartyna Gassowski
Martyna Gassowski
CSClaudia Santos-Hövener
Claudia Santos-Hövener
RZRuth Zimmermann
Ruth Zimmermann
People who inject drugs (PWID) are at increased risk of acquiring and transmitting HIV and Hepatitis C (HCV) due to sharing injection paraphernalia and unprotected sex. To generate seroprevalence data on HIV and HCV among PWID and related data on risk behaviour, a multicentre sero- and behavioural survey using respondent driven sampling (RDS) was conducted in eight German cities between 2011 and 2014. We also evaluated the feasibility and effectiveness of RDS for recruiting PWID in the study cities. Eligible for participation were people who had injected drugs within the last 12 months, were 16 years or older, and who consumed in one of the study cities. Participants were recruited, using low-threshold drop-in facilities as study sites. Initial seeds were selected to represent various sub-groups of people who inject drugs (PWID). Participants completed a face-to-face interview with a structured questionnaire about socio-demographics, sexual and injecting risk behaviours, as well as the utilisation of health services. Capillary blood samples were collected as dried blood spots and were anonymously tested for serological and molecular markers of HIV and HCV. The results are shown as range of proportions (min. and max. values (%)) in the respective study cities. For evaluation of the sampling method we applied criteria from the STROBE guidelines. Overall, 2,077 PWID were recruited. The range of age medians was 29–41 years, 18.5–35.3 % of participants were female, and 9.2–30.6 % were foreign born. Median time span since first injection were 10–18 years. Injecting during the last 30 days was reported by 76.0–88.4 % of participants. Sharing needle/syringes (last 30 days) ranged between 4.7 and 22.3 %, while sharing unsterile paraphernalia (spoon, filter, water, last 30 days) was reported by 33.0–43.8 %. A majority of participants (72.8–85.8 %) reported incarceration at least once, and 17.8–39.8 % had injected while incarcerated. Between 30.8 and 66.2 % were currently in opioid substitution therapy. Unweighted HIV seroprevalence ranged from 0–9.1 %, HCV from 42.3–75.0 %, and HCV-RNA from 23.1–54.0 %. The implementation of RDS as a recruiting method in cooperation with low-threshold drop in facilities was well accepted by both staff and PWID. We reached our targeted sample size in seven of eight cities. In the recruited sample of mostly current injectors with a long duration of injecting drug use, seroprevalence for HIV and HCV varied greatly between the city samples. HCV was endemic among participants in all city samples. Our results demonstrate the necessity of intensified prevention strategies for blood-borne infections among PWID in Germany.

28 March 2024 in Eurosurveillance
Verified
Journal Article
Open access
WCWei Cai
Wei Cai
SKSophie Köndgen
Sophie Köndgen
KTKristin Tolksdorf
Kristin Tolksdorf
RDRalf Dürrwald
Ralf Dürrwald
ESEkkehard Schuler
Ekkehard Schuler
JRJanine Reiche
Janine Reiche
Background: Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. Aim: To describe, for children aged < 5 years, the 2021 and 2022/23 RSV seasons in Germany. Methods: Through data and 16,754 specimens from outpatient sentinel surveillance, we investigated RSV seasonality, circulating lineages, and affected children’s age distributions in 2021 and 2022/23. Available information about disease severity from hospital surveillance was analysed for patients with RSV-specific diagnosis codes (n = 13,104). Differences between RSV seasons were assessed by chi-squared test and age distributions trends by Mann–Kendall test. Results: RSV seasonality was irregular in 2021 (weeks 35–50) and 2022/23 (weeks 41–3) compared to pre-COVID-19 2011/12–2019/20 seasons (median weeks 51–12). RSV positivity rates (RSV-PR) were higher in 2021 (40% (522/1,291); p < 0.001) and 2022/23 (30% (299/990); p = 0.005) than in prior seasons (26% (1,430/5,511)). Known globally circulating RSV-A (lineages GA2.3.5 and GA2.3.6b) and RSV-B (lineage GB5.0.5a) strains, respectively, dominated in 2021 and 2022/23. In 2021, RSV-PRs were similar in 1 – < 2, 2 – < 3, 3 – < 4, and 4 – < 5-year-olds. RSV hospitalisation incidence in 2021 (1,114/100,000, p < 0.001) and in 2022/23 (1,034/100,000, p < 0.001) was approximately double that of previous seasons’ average (2014/15–2019/20: 584/100,000). In 2022/23, proportions of RSV patients admitted to intensive care units rose (8.5% (206/2,413)) relative to pre-COVID-19 seasons (6.8% (551/8,114); p = 0.004), as did those needing ventilator support (6.1% (146/2,413) vs 3.8% (310/8,114); p < 0.001). Conclusions: High RSV-infection risk in 2–4-year-olds in 2021 and increased disease severity in 2022/23 possibly result from lower baseline population immunity, after NPIs diminished exposure to RSV.

1 January 2011 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
WCWei Cai
Wei Cai
CPChristina Poethko-Müller
Christina Poethko-Müller
OHOsamah Hamouda
Osamah Hamouda
DRDoris Md Radun
Doris Md Radun
Background: Data on hepatitis B (HB) infection prevalence among children and adolescents in Germany are scarce. We estimated seroprevalence of HB infection and assessed determinants for HB infection among children and adolescents in Germany from a representative population sample. Methods: From 2003 to 2006, the Robert Koch Institute conducted a nationwide cross-sectional Health Interview and Examination Survey for Children and Adolescents in Germany. Data on age, gender, migration background, and socioeconomic status were collected through questionnaires. A child was defined as having a 2-sided migration background if both parents, or the child and 1 parent, immigrated, and a 1-sided migration background if only 1 parent immigrated. Among children with migration background, a first-generation migrant was defined as born outside Germany; a second-generation migrant was born in Germany. Information on HB vaccination status was obtained from vaccination cards. Serologic samples from participants were tested for anti-hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen. We performed weighted univariable and multivariable logistic regression analyses to assess determinants for HB infection. Results: Of 13,065 participants (3–17 years), 0.5% (95% confidence interval [CI], 0.4–0.7) were anti-HBc positive, among whom 38.7% (95% CI, 20.0–57.5) were hepatitis B surface antigen positive. Two-sided migration background and being a first- or second-generation migrant were significantly associated with anti-HBc positivity (odds ratio [OR]: 8.3, 95% CI: 4.0–17.4; OR: 11.0, 95% CI: 3.5–35.0; OR: 3.0, 95% CI: 1.2–7.3). No further determinants were found. Conclusions: HB infection is rare among children and adolescents in Germany. First- and second-generation migrant children can be considered to be at risk for HB infection, 2-sided migration background or being a first-generation migrant carried the greatest risk. Targeted testing for HB infection and early HB vaccination should be provided to immigrants' children.

29 April 2022 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
WCWei Cai
Wei Cai
RDRalf Dürrwald
Ralf Dürrwald
BBBarbara Biere
Barbara Biere
BSBrunhilde Schweiger
Brunhilde Schweiger
WHWalter Haas
Walter Haas
JRJanine Reiche
Janine Reiche
Based on our national outpatient sentinel surveillance, we have developed a novel approach to determine respiratory syncytial virus (RSV) epidemic seasons in Germany by using RSV positivity rate and its lower limit of 95% confidence interval. This method was evaluated retrospectively on nine RSV seasons, and it is also well‐suited to describe off‐season circulation of RSV in near real time as observed for seasons 2020/21 and 2021/22 during the COVID‐19 pandemic. Prospective application is of crucial importance to enable timely actions for health service delivery and prevention.